Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?

Canadian Journal of Cardiology

Volumn 17, Issue 5 SUPPL. A, 2001, Pages

  Mancini, G B John ^a   Stewart, Duncan J ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

ACE inhibitors; Coronary disease; Diabetes mellitus

Indexed keywords

ALPHA TOCOPHEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIABETIC ANGIOPATHY; FEMALE; HEART DISEASE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DEATH; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; RAMIPRIL; VITAMIN E;

EID: 0035351165     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
2. Yusuf S, Dagenais O, Pogue J, Bosch J, Sleight P, for the Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000;342:154-60.
3. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.